Paclitaxel Albumin-stabilized Nanoparticle Formulation

  (PA-klih-TAK-sil al-BYOO-min-STAY-bih-lized NA-noh-PAR-tih-kul for-myoo-LAY-shun)

This page contains brief information about paclitaxel albumin-stabilized nanoparticle formulation and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Abraxane
FDA Approved:		Yes

FDA Approval for Paclitaxel Albumin-stabilized Nanoparticle Formulation

Paclitaxel albumin-stabilized nanoparticle formulation is approved to be used alone or with other drugs to treat:

• Breast cancer that has recurred (come back) or metastasized (spread to other parts of the body).

• Non-small cell lung cancer that is locally advanced or has metastasized and cannot be treated with surgery or radiation therapy. It is used with carboplatin.

The drug is also called nanoparticle paclitaxel and protein-bound paclitaxel. Nanoparticle paclitaxel causes fewer side effects than paclitaxel.

Nanoparticle paclitaxel is also being studied in the treatment of other types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Paclitaxel - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Find Clinical Trials for Paclitaxel Albumin-stabilized Nanoparticle Formulation - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top